



57th Annual Scientific Session
MARCH 29 – APRIL 1 • CHICAGO

FOR IMMEDIATE RELEASE

March 28, 2008

CONTACT: Andrew Crosby
(901) 237-6927
acrosby@crosbyvolmer.com
Amy Murphy
(240) 328-4549
amurphy@acc.org
ACC.08 Newsroom:
(312) 949-3450

ACC.08 Conference Schedule

Chicago, IL – The following is a schedule of press conferences and media availability for the American College of Cardiology's 57th Annual Scientific Session, in partnership with the Society for Cardiovascular Angiography and Interventions (SCAI) ACCi2 Summit, at the McCormick Place Convention Center in Chicago, IL on March 29th – April 1st.

All media availability and press conferences will be held in Room E270 of the McCormick Place Convention Center.

Saturday, March 29

9:45 a.m. – 10:45 a.m. CDT

What: SCAI-ACCi2 LBCT Press Conference
MATERIAL EMBARGOED UNTIL 8:00 a.m. CDT
Sessions from 8:00 a.m. – 9:30 a.m. CDT

(2401-1) A Randomized, Double-Blind, Active-Controlled, Multi-Center Trial (ISAR-REACT 3) of Bivalirudin Versus Unfractionated Heparin in Troponin-Negative Patients Undergoing Percutaneous Coronary Interventions After Pre-Treatment With 600 mg of Clopidogrel

(2401-2) Eight Months Angiographic Follow-up in Patients Randomized to Crush or Culotte Bifurcation Stenting: The Nordic Stent Technique Study

(2401-3) High Recurrence Rates After a First Episode of Stent Thrombosis: Results From the Dutch Stent Thrombosis Study

(2401-4) Platelet Monitoring of Clopidogrel Response Using VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients with Clopidogrel Resistance: A Multicentre Randomized Prospective Study

(2401-5) Prasugrel Compared to Clopidogrel in Patients With Acute Coronary Syndromes Undergoing PCI With Stenting: The TRITON - TIMI 38 Stent Analysis

(2401-6) Percutaneous Coronary Interventions at Facilities Without On-Site Cardiac Surgery: A Report From the National Cardiovascular Data Registry (NCDR)

11:00 a.m. – 12:00 p.m. CDT

**What: Press Conference
ACC.08 “Consumer Interest: What Your Audience Didn’t Know”
FOR IMMEDIATE RELEASE at 11 a.m. CDT**

(1029-100) Sudden Death and the Anniversary Effect

(1035-204) Morbid Obesity Abolishes Gender Differences in Cardiovascular Risk Factors

(1028-227) Long-Term Prognosis Factors of Young Patients (less than 35 years) having Acute MI: The Detrimental Role of the Continuation of Smoking

(1035-229) Declining Anxiety Level Improves Prognosis in Patients with Coronary Artery Disease

(1007-222) Decreased Antibody Responses to Influenza Vaccine in Heart Failure Patients

5:30 p.m. – 6:30 p.m. CDT

Media Welcome Reception

Sunday, March 30

9:45 a.m. – 10:45 a.m. CDT

What: SCAI-ACCi2 LBCT Session

MATERIAL EMBARGOED UNTIL 8:00 a.m. CDT

(2404-1) Comparison of Angioplasty With Infusion of Tirofiban or Abciximab and With Implantation of Sirolimus-Eluting or Uncoated Stents for the Treatment of Acute Myocardial Infarction

(2404-2) Long-Term Clinical Outcomes Following Drug-Eluting and Bare-Metal Stenting for Acute Myocardial Infarction in Massachusetts

(2404-3) Trial of Routine ANgioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI)

(2404-4) Pretreatment With a High Loading Dose of Clopidogrel and Value of Abciximab During Primary Coronary Intervention in Patients With Acute Myocardial Infarction. Results of the Randomized BRAVE-3 Trial

(2404-5) Vascular Protection in High-Risk Non-ST Elevation Acute Coronary Syndromes: The Angioplasty Balloon-Associated Coronary Debris and the EZ FilterWire (A-F) Randomized, Controlled Trial

(2404-6) Thrombus Aspiration During Coronary Angioplasty for Acute Myocardial Infarction

11:30 a.m. – 1:00 p.m. CDT

**ACC.08: Opening Session (including ENHANCE Trial)
EMBARGOED UNTIL 12:00 p.m. CDT**

Monday, March 31

9:45 a.m. CDT

What: Press Conference: SCAI-ACCi2 LBCT

MATERIAL EMBARGOED UNTIL 8:00AM

Sessions from 8:00 a.m. – 9:30 a.m. CDT

(2407-1) SPIRIT II Study: A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With *De Novo* Native Coronary Artery Lesions

(2407-2) Safety and Efficacy Outcomes of Dual Pimecrolimus/Paclitaxel Drug Delivery Versus Single Drug Delivery Using Conor Reservoir Technology: GENESIS Trial Six-Month Results

(2407-3) Paclitaxel-Eluting Devices: Randomized Comparison of the SeQuent™ Please Balloon Catheter Versus the Taxus™ Stent in the Treatment of In-Stent-Restenosis - 12-Month Follow-up of the PEPCAD II ISR Study

(2407-4) 12-Month Clinical Outcome of Prospective Multicenter Registry of Excel™ Biodegradable Polymer Sirolimus Eluting Stents (CREATE)

(2407-5) Long-Term Outcomes of Stent Implantation Versus Coronary Artery Bypass Surgery for the Treatment of Unprotected Left Main Coronary Disease

(2407-6) Duration of Dual Antiplatelet Therapy After Sirolimus Eluting Stent for Off-Label Indications: Results of the MATRIX Registry

11:45 a.m. – 12:45 p.m. CDT

**What: Press Conference: ACC.08 Late-Breaking Clinical Trials I
MATERIAL EMBARGOED UNTIL 10 a.m.
Sessions from 10:00 a.m. – 11:30 a.m. CDT**

(407-1) Results of the ONTARGET Study Comparing Ramipril With Telmisartan, and Its Combination in High-Risk Individuals Without Heart Failure

(407-2) Avoiding Cardiovascular Events Through COMbination Therapy in Patients LIVING with Systolic Hypertension, the Early Termination of the ACCOMPLISH Trial for Efficacy

(407-3) The Hypertension in the Very Elderly Trial (HYVET): Main Results

(407-4) Effect of Rosuvastatin Therapy on Coronary Artery Stenoses in the ASTEROID Trial

(407-5) Effect of Pioglitazone Versus Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes (PERISCOPE)

(407-6) Cardiovascular Risk of Celecoxib in Six Randomized Placebo-Controlled Trials: The Cross-Trials Safety Assessment Pooled Analysis

2:45 p.m. CDT

**What: ACC.08 Late-Breaking Abstracts I Media Availability
MATERIAL EMBARGOED UNTIL 1 PM CDT
Sessions from 1:00 p.m. – 2:45 p.m. CDT**

Immediately following the ACC.08 Late-Breaking Abstract Session, ACC Staff Will Coordinate Press Interviews and Arrange Availabilities in the ACC Newsroom

(409-1) Effect of the Direct Renin Inhibitor Aliskiren, Either Alone or in Combination With Losartan, Compared to Losartan, on Left Ventricular Mass in Patients With Hypertension and Left Ventricular Hypertrophy: The Aliskiren Left Ventricular Assessment of Hypertrophy (**ALLAY**) Trial

(409-2) Echocardiographic Tissue Doppler Imaging Is a Powerful Independent Prognosticator of Overall Mortality in the General Population. Results From the **Fourth** Copenhagen City Heart Study (2002-2007)

(409-3) Efficacy and Safety of the Selective Adenosine A_{2A} Receptor Agonist Binodenoson for Pharmacologic Stress: Results of a Phase 3, Randomized, Double-Blind, Risk-Stratified, Active-Controlled, Crossover Trial

(409-4) Effects of Aggressive Versus Conventional Lipid-Lowering Therapy by Atorvastatin on Inflammatory Activity in Human Carotid Atherosclerotic Plaques: A Prospective Randomised Double-Blind Trial With USPIO-Enhanced High Resolution Magnetic Resonance Imaging

(409-5) Safety and Efficacy of Commercially Available Ultrasound Contrast Agents in a Clinical Setting

(409-6) International PROspective Multicenter Study On RadiaTion Dose Estimates Of Cardiac CT AngIOgraphy IN Daily Practice

(409-7) Effects of a Selective Inhibitor of Secretory Phospholipase A₂ on Low Density Lipoproteins and Inflammatory Pathways

Tuesday, April 1

8:30 a.m. – 9:30 a.m. CDT

**What: Press Conference: ACC.08 Late-Breaking Clinical Trials II
MATERIAL EMBARGOED UNTIL 8:30 a.m. (unless otherwise noted)**

(412-1) Effect of Rimonabant on Progression of Atherosclerosis in Patients With Abdominal Obesity and Coronary Artery Disease (STRADIVARIUS)

(412-2) Results of the Home Automatic External Defibrillator Trial (HAT)

(412-3) 12-Month Results of the REVERSE Study

(412-4) Long-Term Cardiac Arrhythmias Recorded by an Insertable Loop Recorder in Patients With Reduced Ejection Fraction After Acute Myocardial Infarction: The CARISMA Study

(412-5) The TRENDS Study: Is There a Critical Value of Daily Atrial Tachyarrhythmia Burden From Device Diagnostics That Raises Stroke Risk?

(412-6) Societal Cost and Cost to Medicare for Enhanced Monitoring Using a Computer-Based Telephonic Monitoring System in Older Patients With Heart Failure: The Heart Failure Home Care Trial

12:15 p.m. – 1:15 p.m. CDT

**What: Press Conference: SCAI-ACCi2 LBCT
MATERIAL EMBARGOED UNTIL 10:30 a.m.
Sessions from 10:30 a.m. – 12:00 p.m. CDT**

(2411-1) Percutaneous Mitral Repair With the MitraClip[®] Device for Functional Mitral Regurgitation: Acute Success, One-Year Durability and Reverse LV Remodeling in the Initial EVEREST Cohort

(2411-2) The Impact of Renal Artery Revascularisation in Atherosclerotic Renovascular Disease: The Angioplasty and Stenting for Renal Artery Lesions (ASTRAL) Trial

(2411-3) Randomized Clinical Trial to Compare the Nephrotoxic Effects of Iso-Osmolar Versus Low-Osmolar Contrast Medium in Patients With Impaired Renal Function Undergoing Percutaneous Coronary Intervention: The COntrast Media and NephroToxicity Following Coronary Revascularization by Angioplasty (CONTRAST) Study

(2411-4) ECLIPSE Trial: Ensure's Vascular Closure Device Speeds Hemostasis

(2411-5) Final Results of a Phase I/II, Randomized, Open-Label Trial to Evaluate Intramyocardial Autologous Skeletal Myoblast Transplantation in Congestive Heart Failure Patients: The SEISMIC Trial

(2411-6) Clopidogrel Reloading Before Percutaneous Coronary Intervention Improves Outcome in Patients With Acute Coronary Syndromes Receiving Chronic Clopidogrel Therapy. Results of the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-RELOAD (ARMYDA-RELOAD) Randomized Trial

2:30 p.m. CDT

**Who: ACC.08 Late-Breaking Abstracts II Media Availability
MATERIAL EMBARGOED UNTIL 1 p.m.
Sessions from 1:00 p.m. – 2:30 p.m. CDT**

Immediately following the ACC Late-Breaking Abstract Session, ACC Staff Will Coordinate Press Interviews and Arrange Availabilities in the ACC Newsroom

(413-1) A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk Coronary Artery Bypass Graft (CABG) Surgery: Primary Results of the MEND-CABG II Trial

(413-2) Results of a Multicenter Randomized Double-Blind Placebo-Controlled Study to Assess the Benefit and Safety of Rosiglitazone in Preventing Atherosclerosis Progression After Coronary Artery Bypass Surgery in Type 2 Diabetes

(413-3) Results of the ON-TIME 2 Trial: Prehospital Tirofiban in STEMI

(413-4) Efficacy and Safety of Continuous Aortic Flow Augmentation in Patients Hospitalized With Acute Decompensated Heart Failure: Results of the MOMENTUM Trial

(413-5) Effects of Rolofylline, a New Adenosine A₁ Receptor Antagonist, on Symptoms, Renal Function and Outcomes in Patients With Acute Heart Failure: Results of the PROTECT Pilot Study

(413-6) Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Inotropic Agent With Lusitropic Properties, in Acute Heart Failure Syndromes (HORIZON-HF)

